| No. of patients enrolled | 399 (100%) |
| Exclusion during VAD regimen | 101 (25.3%) |
| Progressive disease | 39 |
| Severe infectious complications | 29 |
| Cardiac failure | 9 |
| Patient's decision | 8 |
| Protocol violation | 5 |
| Renal failure | 5 |
| Toxic death | 5 |
| Suicide | 1 |
| No. of patients randomized | 298 (74.7%) |
| No. of patients inevaluable for HDT | 16 (4%) |
| Progression before ASCT | 7 |
| Patient's decision | 4 |
| Infectious death before ASCT | 2 |
| Protocol violation | 2 |
| Suicide | 1 |
| No. of patients evaluable | 282 (70.7%) |
| Arm A: TBI + HDM140 | 140 |
| Arm B: HDM200 | 142 |
| No. of patients enrolled | 399 (100%) |
| Exclusion during VAD regimen | 101 (25.3%) |
| Progressive disease | 39 |
| Severe infectious complications | 29 |
| Cardiac failure | 9 |
| Patient's decision | 8 |
| Protocol violation | 5 |
| Renal failure | 5 |
| Toxic death | 5 |
| Suicide | 1 |
| No. of patients randomized | 298 (74.7%) |
| No. of patients inevaluable for HDT | 16 (4%) |
| Progression before ASCT | 7 |
| Patient's decision | 4 |
| Infectious death before ASCT | 2 |
| Protocol violation | 2 |
| Suicide | 1 |
| No. of patients evaluable | 282 (70.7%) |
| Arm A: TBI + HDM140 | 140 |
| Arm B: HDM200 | 142 |